ArticleJournal of the American Heart Association2026
Correlates and Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Assay in Congenitally Corrected Transposition of the Great Arteries.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular biomarkers such as NT-proBNP (N-terminal pro-B-type natriuretic peptide) are used for heart failure risk stratification in patients with acquired heart disease, but there are limited data about its role in patients with congenitally corrected transposition of the great arteries. The current study aims to assess the role of serial NT-proBNP measurements for risk stratification in adults with congenitally corrected transposition of the great arteries.
methodsWe studied adults with congenitally corrected transposition of the great arteries with ≥2 NT-proBNP measurements (2003-2024). Temporal change in NT-proBNP was calculated as relative change from baseline levels.
resultsOf 152 patients (age 47±13 years, 45% men), baseline NT-proBNP was 539 (interquartile range, 193-1549) pg/mL, and relative change from baseline levels of NT-proBNP was 34% (interquartile range, -11 to 67). Of 152 patients, 45 (30%) had cardiovascular events (heart failure hospitalization [n=29], ventricular assist device [n=5], heart transplantation [n=11], and death [n=10]), yielding a 10-year incidence of 26%. Higher baseline NT-proBNP and relative change from baseline levels were associated with cardiovascular events. Serial NT-proBNP measurements had incremental prognostic value compared with baseline measurement. The correlates of higher NT-proBNP levels were atrial fibrillation, hypertension, right ventricular dilation and dysfunction, and atrioventricular valve regurgitation. Renin-angiotensin-aldosterone system antagonist was associated with lower NT-proBNP levels and lower risk of cardiovascular events.
conclusionsNT-proBNP testing is inexpensive, widely available, and noninvasive, making it well suited for longitudinal surveillance in adults with congenital heart disease. Most of the correlates for elevated NT-proBNP levels were modifiable, providing target for therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.